Walid AbiSaab - Galapagos Executive
| GLPG Stock | EUR 25.50 0.20 0.78% |
Executive
Dr. Walid AbiSaab, M.D. was Member of the Executive Committee, Chief Medical Officer of Galapagos NV since March 2017. He drives the overall medical strategy of the Company and is responsible for late stage clinical development and operations, medical and regulatory affairs, and safety. Before, hebworked at Shire Pharmaceuticals where he held various clinical development leadership roles, most recently as Group Vice President, Global Clinical Development Therapeutic Area Head, Gastrointestinal, Endocrinology and Metabolism. Prior to that, he led clinical development activities at Novartis, Abbott Laboratories and Pfizer, addressing a wide range of therapeutic areas and leading teams throughout the clinical development process. Under his leadership, more than 30 molecules have advanced through clinical development leading to several approvals in the US, EU and Canada. Prior to his pharma roles, he was Assistant Professor of Psychiatry and Neurosurgery at Yale University Medical School, where he headed their Schizophrenia Research at the Clinical Neuroscience Research Unit and the Neurosurgery Epilepsy Microdialysis Research Program since 2017.
| Age | 58 |
| Tenure | 7 years |
| Phone | 32 1 534 29 00 |
| Web | https://www.glpg.com |
Galapagos Management Efficiency
The company has return on total asset (ROA) of (0.0119) % which means that it has lost $0.0119 on every $100 spent on assets. This is way below average. Galapagos' management efficiency ratios could be used to measure how well Galapagos manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | EXECUTIVE Age | ||
| Ben Wishart | Koninklijke Ahold Delhaize | 61 | |
| Abbe Luersman | Koninklijke Ahold Delhaize | 51 | |
| Jan Groot | Koninklijke Ahold Delhaize | 60 | |
| Mary Citrino | Koninklijke Ahold Delhaize | 60 | |
| Rene Graafland | Koninklijke Ahold Delhaize | 64 | |
| Wim Buyens | Barco NV | 54 | |
| Ben Noteboom | Koninklijke Ahold Delhaize | 61 | |
| Dominique Leroy | Koninklijke Ahold Delhaize | 55 | |
| Farhan Siddiqi | Koninklijke Ahold Delhaize | 51 | |
Management Performance
| Return On Equity | 0.0021 | |||
| Return On Asset | -0.0119 |
Galapagos NV Leadership Team
Elected by the shareholders, the Galapagos' board of directors comprises two types of representatives: Galapagos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galapagos. The board's role is to monitor Galapagos' management team and ensure that shareholders' interests are well served. Galapagos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galapagos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth Goodwin, VP Corporate Communications & Investor Relations | ||
| Andre Hoekema, Senior Vice President - Corporate Development | ||
| John Montana, Managing Argenta | ||
| Michele MBA, Chief Board | ||
| Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer | ||
| Marieke Vermeersch, Head Communication | ||
| Chantal Tasset, Head Devel | ||
| Sofie Gijsel, Head Relations | ||
| MBA MBA, COO Pres |
Galapagos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galapagos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0021 | |||
| Return On Asset | -0.0119 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | (0.17) % | |||
| Current Valuation | (2 B) | |||
| Shares Outstanding | 65.84 M | |||
| Shares Owned By Insiders | 26.24 % | |||
| Shares Owned By Institutions | 32.13 % | |||
| Price To Earning | (146.88) X | |||
| Price To Book | 0.87 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Galapagos Stock Analysis
When running Galapagos' price analysis, check to measure Galapagos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galapagos is operating at the current time. Most of Galapagos' value examination focuses on studying past and present price action to predict the probability of Galapagos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galapagos' price. Additionally, you may evaluate how the addition of Galapagos to your portfolios can decrease your overall portfolio volatility.